Ascidian and Lilly $1.9B Deal for Kidney RNA Editing | Lucid Diligence Brief
Ascidian and Lilly $1.9B collaboration tests whether RNA exon editing can move…
Servier Edgewise Sevasemten Deal | Lucid Diligence Brief
Servier’s Edgewise acquisition puts sevasemten’s Becker muscular dystrophy data…
Secretome STM-01 Duchenne Cardiomyopathy | Lucid Diligence Brief
Secretome’s STM-01 faces Duchenne cardiomyopathy endpoint, CMC, and regulatory…
Lucid Diligence Brief: Genethon and Ampersand Biomedicines AAV Partnership
Lucid Diligence Brief: Genethon and Ampersand Biomedicines partner to design…
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic partnership for late-phase AAV manufacturing
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic…
Lucid Diligence Brief: Blackstone Life Sciences $250 million investment in Anagram Therapeutics
Lucid Diligence Brief: Blackstone Life Sciences $250 million investment in…
Lucid Diligence Brief: Apertura Gene Therapy and TSC Alliance Collaboration
Lucid Diligence Brief: Apertura Gene Therapy and TSC Alliance Collaboration…
Lucid Diligence Brief: Chiesi to acquire KalVista Pharmaceuticals
Lucid Diligence Brief: Chiesi to acquire KalVista Pharmaceuticals Professional…
Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J
Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J…
Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in Sarcoma
Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in…
Lucid Diligence Brief: Tenaya Therapeutics and Alnylam Cardiovascular Collaboration
Lucid Diligence Brief: Tenaya Therapeutics and Alnylam Cardiovascular…
Lucid Diligence Brief: Angelini Pharma collaboration with Quiver Bioscience on genetic epilepsies
Lucid Diligence Brief: Angelini Pharma collaboration with Quiver Bioscience on…